Neoadjuvant chemotherapy for high-risk prostatic adenocarcinoma.

docetaxel neoadjuvant chemotherapy prostate cancer prostatectomy prostatic adenocarcinoma

Journal

IJU case reports
ISSN: 2577-171X
Titre abrégé: IJU Case Rep
Pays: Australia
ID NLM: 101764958

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 31 07 2018
accepted: 03 11 2018
entrez: 4 8 2020
pubmed: 28 1 2019
medline: 28 1 2019
Statut: epublish

Résumé

Neoadjuvant chemotherapy in high-risk, locally advanced prostate cancer remains an understudied area of prostate cancer. Chemotherapy continues to be a viable option. The combination with surgery may be desired but lacks data for complete recommendation. We demonstrate the successful utilization of chemotherapy in the neoadjuvant arena. A 70-year-old male was diagnosed with high-risk prostate cancer on biopsy. Upon multiparametric magnetic resonance imaging, the patient had local rectal wall invasion and stage T4 N0 M0 after a negative bone scan. After treatment with androgen-deprivation therapy and docetaxel, repeat multiparametric magnetic resonance imaging showed regression of rectal invasion. The patient elected for prostatectomy and avoided proctectomy and colostomy. The patient's postoperative prostate-specific antigen was undetectable on initial follow-up. We show that neoadjuvant chemotherapy merits further study and may provide a more permanent surgical option for patients.

Identifiants

pubmed: 32743374
doi: 10.1002/iju5.12031
pii: IJU512031
pmc: PMC7292178
doi:

Types de publication

Case Reports

Langues

eng

Pagination

61-64

Informations de copyright

© 2019 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
BMC Cancer. 2018 Apr 2;18(1):354
pubmed: 29606109
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Eur Urol. 2016 Jan;69(1):16-40
pubmed: 26427566
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
Eur Urol Focus. 2015 Sep;1(2):173-184
pubmed: 28723431
N Engl J Med. 2018 Apr 12;378(15):1408-1418
pubmed: 29420164

Auteurs

Robert Brunner (R)

Department of Urology College of Medicine and Life Sciences The University of Toledo Toledo Ohio USA.

Bradley Buck (B)

Department of Urology College of Medicine and Life Sciences The University of Toledo Toledo Ohio USA.

Zane Giffen (Z)

Department of Urology College of Medicine and Life Sciences The University of Toledo Toledo Ohio USA.

Daniel Murtagh (D)

Department of Urology College of Medicine and Life Sciences The University of Toledo Toledo Ohio USA.

Terrence Lewis (T)

Department of Radiology College of Medicine and Life Sciences The University of Toledo Toledo Ohio USA.

Cara Gatto-Weis (C)

Department of Pathology College of Medicine and Life Sciences The University of Toledo Toledo Ohio USA.

Puneet Sindhwani (P)

Department of Urology College of Medicine and Life Sciences The University of Toledo Toledo Ohio USA.

Classifications MeSH